Literature DB >> 32631185

Cannabis as a Gateway Drug for Opioid Use Disorder.

Arthur Robin Williams1.   

Abstract

Cannabis use in some individuals can meaningfully introduce de novo risk for the initiation of opioid use and development of opioid use disorder. These risks may be particularly high during adolescence when cannabis use may disrupt critical periods of neurodevelopment. Current research studying the combination of genetic and environmental factors involved in substance use disorders is poorly understood. More research is needed, particularly to identify which adolescents are most at risk and to develop effective interventions addressing contributing factors such as trauma and psychiatric comorbidity.

Entities:  

Mesh:

Year:  2020        PMID: 32631185      PMCID: PMC7359408          DOI: 10.1177/1073110520935338

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN: 1073-1105            Impact factor:   1.718


  37 in total

1.  States Move to Substitute Opioids With Medical Marijuana to Quell Epidemic.

Authors:  Rebecca Voelker
Journal:  JAMA       Date:  2018-12-18       Impact factor: 56.272

2.  Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States.

Authors:  Mark Olfson; Melanie M Wall; Shang-Min Liu; Carlos Blanco
Journal:  Am J Psychiatry       Date:  2017-09-26       Impact factor: 18.112

3.  Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence.

Authors:  Catherine Orr; Philip Spechler; Zhipeng Cao; Matthew Albaugh; Bader Chaarani; Scott Mackey; Deepak D'Souza; Nicholas Allgaier; Tobias Banaschewski; Arun L W Bokde; Uli Bromberg; Christian Büchel; Erin Burke Quinlan; Patricia Conrod; Sylvane Desrivières; Herta Flor; Vincent Frouin; Penny Gowland; Andreas Heinz; Bernd Ittermann; Jean-Luc Martinot; Marie-Laure Paillère Martinot; Frauke Nees; Dimitri Papadopoulos Orfanos; Tomáš Paus; Luise Poustka; Sabina Millenet; Juliane H Fröhner; Rajiv Radhakrishnan; Michael N Smolka; Henrik Walter; Robert Whelan; Gunter Schumann; Alexandra Potter; Hugh Garavan
Journal:  J Neurosci       Date:  2019-01-14       Impact factor: 6.167

4.  Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence.

Authors:  Kenneth S Kendler; John Myers; Carol A Prescott
Journal:  Arch Gen Psychiatry       Date:  2007-11

5.  Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates Than Newer 'Medicalized' Programs.

Authors:  Arthur Robin Williams; Mark Olfson; June H Kim; Silvia S Martins; Herbert D Kleber
Journal:  Health Aff (Millwood)       Date:  2016-03       Impact factor: 6.301

6.  Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons.

Authors:  Marco Pistis; Simona Perra; Giuliano Pillolla; Miriam Melis; Anna Lisa Muntoni; Gian Luigi Gessa
Journal:  Biol Psychiatry       Date:  2004-07-15       Impact factor: 13.382

Review 7.  Candidate genes for cannabis use disorders: findings, challenges and directions.

Authors:  Arpana Agrawal; Michael T Lynskey
Journal:  Addiction       Date:  2009-04       Impact factor: 6.526

8.  Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55,940 on morphine self-administration behaviour and the endogenous opioid system.

Authors:  Miguel Biscaia; Beatriz Fernández; Alejandro Higuera-Matas; Miguel Miguéns; Maria-Paz Viveros; Carmen García-Lecumberri; Emilio Ambrosio
Journal:  Neuropharmacology       Date:  2008-02-01       Impact factor: 5.250

9.  Association between medical cannabis laws and opioid overdose mortality has reversed over time.

Authors:  Chelsea L Shover; Corey S Davis; Sanford C Gordon; Keith Humphreys
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-10       Impact factor: 11.205

10.  Adolescent exposure to Δ9-tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture of prefrontal pyramidal neurons.

Authors:  Michael L Miller; Benjamin Chadwick; Dara L Dickstein; Immanuel Purushothaman; Gabor Egervari; Tanni Rahman; Chloe Tessereau; Patrick R Hof; Panos Roussos; Li Shen; Mark G Baxter; Yasmin L Hurd
Journal:  Mol Psychiatry       Date:  2018-10-03       Impact factor: 15.992

View more
  2 in total

1.  Marijuana use does not affect weight loss or complication rate after bariatric surgery.

Authors:  Tarin Worrest; C Cole Malibiran; Jill Welshans; Elizabeth Dewey; Farah Husain
Journal:  Surg Endosc       Date:  2022-01-13       Impact factor: 3.453

2.  The dopamine transporter gene SLC6A3: multidisease risks.

Authors:  Maarten E A Reith; Sandhya Kortagere; Corinde E Wiers; Hui Sun; Manju A Kurian; Aurelio Galli; Nora D Volkow; Zhicheng Lin
Journal:  Mol Psychiatry       Date:  2021-10-14       Impact factor: 13.437

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.